Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response
about
Correlated immunohistochemical and cytological assays for the prediction of hematogenous dissemination of breast cancerHuman Mena associates with Rac1 small GTPase in glioblastoma cell linesH1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix(®) vaccination.Ena drives invasive macrophage migration in Drosophila embryos.The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behaviorImmunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells.Enhancing cellular cancer vaccinesThe cooperation between hMena overexpression and HER2 signalling in breast cancerTumor microenvironment of metastasis and risk of distant metastasis of breast cancer.MENA is a transcriptional target of the Wnt/beta-catenin pathway.MALDI mass spectrometric imaging based identification of clinically relevant signals in prostate cancer using large-scale tissue microarrays.Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo.Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous disseminationMolecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer.Mena invasive (Mena(INV)) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEMPost-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation.Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.Expression and Distribution Characteristics of Human Ortholog of Mammalian Enabled (hMena) in GliomaThe phosphorylation status of VASP at serine 322 can be predictive for aggressiveness of invasive ductal carcinoma.Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer.Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell linesInsulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasisOncogenic alternative splicing switches: role in cancer progression and prospects for therapy.The enabled homolog gene polymorphisms are associated with susceptibility and progression of childhood IgA nephropathy.The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.Identifying autoantibody signatures in cancer: a promising challenge.Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions.Metastasis: tumor cells becoming MENAcing.The immunoregulatory mechanisms of carcinoma for its survival and developmentNew targets for the immunotherapy of colon cancer-does reactive disease hold the answer?Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis.hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.Cell matrix adhesions in cancer: The proteins that form the glue.Regulation of VASP by phosphorylation: consequences for cell migration.The significance of ENAH in carcinogenesis and prognosis in gastric cancer.The possible role of Mena protein and its splicing-derived variants in embryogenesis, carcinogenesis, and tumor invasion: a systematic review of the literature.hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?Expression of the cytoskeleton regulatory protein Mena in human gastric carcinoma and its prognostic significance.
P2860
Q27027372-3685B989-6561-4744-B7DA-075125E7EB2AQ27350493-F529296F-4A13-4288-B4CB-0745B41A5284Q30371297-9CD65286-DC95-479D-9F45-5EC5541BD7E4Q30497735-3CCFAEDA-5F7B-4538-98AC-CB6A802F3178Q30823188-24FE4580-1D1B-4BB9-B3F6-98A85FADFCB9Q33215427-118EB5AD-E565-4E67-BC5A-CA28D72210AAQ33547396-8AD4231C-3440-4DF1-95A7-CB8533928D6EQ33786779-6574D285-2EBA-4862-8225-D6B05401F75CQ34048120-722D513F-EB4F-4D05-81F0-C0390F01DF99Q34277630-34562541-E822-4F5F-8D11-1E40EFCFE9A3Q34574636-110CFC48-8A8C-4A1E-BF86-EC6398A85122Q34592450-CB9B29DC-EF62-477A-86BF-3AECD422CA04Q35165988-0C8BC28E-BFA6-4D19-83F1-72808EAD5DE0Q35165997-528EA8D5-EE34-4D71-9CC6-5AB6098ED002Q35674829-109C071F-C791-40D0-A41E-12A16011A7F1Q36283722-1F3AD26D-012A-42DC-A9A8-551B24EFE3DDQ36398266-7F137B42-565C-49A8-903F-BEEA15BD798DQ36436933-FB5C2715-9982-4270-AF2D-D415CA3DCBEBQ36551102-D6A6E7E9-CBD5-482B-B2C1-8D7A48B16261Q36557418-F6DF0DBF-4548-490F-B2BC-29888DEBE387Q36709561-E6503C26-A59F-4502-9F9A-F3461CC7486DQ36982771-AF40B37E-74CC-4927-B98B-68CDFCE09FFFQ37001399-F6315EC9-FD30-4C8E-987D-9E88B826E70CQ37087081-26F0CA0C-6B3A-4913-A203-5FC060A0B7A6Q37304724-5F862ECD-FDA6-48A6-893C-D43741D97181Q37459389-5A73B6BF-DC79-4767-8E35-4D09E529C4A7Q37557707-060256C5-1A6F-499E-AD3E-BD077EAB8B47Q37579900-3574B99C-0783-4C6D-A783-59B20E37AB70Q37582688-8E4EC962-C0C4-4C13-9462-49A94F39EF02Q37808845-9B477CFE-6BA6-4D6C-9CEE-66E0F542A739Q37831426-66B9AF5D-1A5B-4766-A496-CA6A09A8C536Q38089480-90EF3CC4-72EA-41B3-83C9-B35E5EA29F8AQ38780263-DDD072D3-1D8F-44D8-A45D-4744ECB073F9Q38876630-3CA584C4-CE6A-4760-9925-E00D9BF8B6F6Q39286100-EF6041AD-0DE9-4CF0-A0B6-82E9A146A7DFQ41920997-7CC6F305-1214-4B1A-9039-02BAFB219F56Q42654046-49BD6D87-3FC9-4236-81E5-8020D6D6DC2BQ43067141-231E15D2-421B-4B89-9066-95B6D2FBA9C0Q45904310-A7D5098B-D433-4704-BCB9-B296A02B373DQ46053682-49D7BED4-6A0A-4AFC-B011-BD99EDA9C40A
P2860
Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@ast
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@en
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@nl
type
label
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@ast
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@en
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@nl
prefLabel
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@ast
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@en
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@nl
P2093
P2860
P50
P3181
P356
P1476
Human Mena protein, a serex-de ...... nd CD8+ T-cell immune response
@en
P2093
Angela Santoni
Claudio Botti
Duilia Del Bello
Elke Jager
Francesca Di Modugno
Giovanna Bronzi
Irene Venturo
Matthew J Scanlan
Paola Nisticò
Simona Cascioli
P2860
P304
P3181
P356
10.1002/IJC.20094
P407
P577
2004-05-10T00:00:00Z